The performance of Morgan Stanley’s MS trading business (constituting a significant portion of its top line) is expected to ...

Morgan Stanley is a buy on weakness with strong dividend growth and projected revenue growth in Q4 2024 and early 2025. Click for our MS earnings preview.

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

Wall Street’s largest investment banks are looking to award traders and dealmakers with their largest bonus increases since the pandemic, with ...

Morgan Stanley Investment Management (MSIM) announced today that the 1GT private climate equity strategy (1GT) participated in a ?115 million fundraise for XOCEAN (company), a leading provider of ...

Global equity issuance rose 20% last year, but stock market launches have so far lagged that increase, remaining far below ...

Andrew Forrest has taken a ‘bring it on’ stance in response to ExxonMobil’s defamation lawsuit, which it has filed against ...

Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 ...

Wall Street's biggest banks are set to reward their traders and dealmakers with their biggest bonus increase since the ...

The latest Market Talks covering Financial Services. Exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

(Reuters) - Top Wall-Street brokerages revised their Fed rate cut forecasts, after a blow-out U.S. jobs report on Friday, ...